HIV treatment and prevention strategies for adolescents in South Africa
Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value
This study is looking to create better ways to treat and prevent HIV for young people aged 10 to 24 in South Africa, focusing on their specific needs and challenges, so they can have healthier lives without the hassle of daily medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10907591 on NIH RePORTER |
What this research studies
This research focuses on developing tailored HIV treatment and prevention strategies specifically for adolescents and young adults aged 10 to 24 in South Africa, where HIV rates are alarmingly high. It aims to address the unique challenges faced by this age group, including stigma, medication adherence, and late diagnosis. By utilizing advanced modeling techniques, the project will evaluate the clinical benefits and cost-effectiveness of new long-acting HIV prevention and treatment options that do not require daily medication. The goal is to improve health outcomes and access to care for young people living with or at risk of HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research include adolescents and young adults aged 10 to 24 who are living with HIV or are at high risk of contracting the virus.
Not a fit: Patients outside the age range of 10 to 24 or those not affected by HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce HIV-related mortality and improve the quality of life for adolescents and young adults in South Africa.
How similar studies have performed: Previous research has shown success in using similar modeling approaches to improve HIV treatment and prevention strategies in other populations.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Neilan, Anne — Massachusetts General Hospital
- Study coordinator: Neilan, Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.